BRAF and melanoma: The combinations of atezolizumab (anti-PD-L1) with sunitinib (VEGFR inhibitor), and pembrolizumab (anti-PD1) with dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) are under phase 3 and phase 2 clinical trials in metastatic RCC and BRAF-mutant melanoma, respectively [17].